References
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705
- Osrskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagon-like peptide-17–36 amide and glucagon-like peptide-17–37 in healthy subjects are indistinguishable. Diabetes 1993;42: 658–61
- Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptides 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 1995;44: 1126–31
- Marguet D, Baggio L, Kobyashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874–9
- Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874–80
- Ristic S, Byiers S, Foley J, Homes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692–8
- Ahren B, Pacini G, Foley JE, Scheweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936–40
- Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888–94
- He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmaco-dynamics of vildagliptinin patients with type 2 diabetes mellitus. Clin Pharmacokinetics 2007;46:577–88
- Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007;47:1152–8
- Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health-Syst Pharm 2007;64: 1265–73
- Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug. Drug Metab Disp 1990;18:138–45
- Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191–9
- Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxyl acid is mediated primarily by CYP3A and not CYP2D6. Br J Clin Pharmacol 2003;56: 120–4
- Neuuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63: 332–41
- Hsyu PH, Schultz Smith MD, Lillibridge JH, et al. Pharmaco-kinetic interactions between nelfinavir and 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimirob Agents Chemother 2001;45: 3445–50
- Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinetics 1993;24:195–202
- Guidance for Industry. Drug interaction studies – study design, data analysis, and implications for dosing and labeling. September 2006;http://www.fda.gov/cder/guidance/6695dft.htm